MannKind Q3 total revenue $70M (+37% YoY); YTD net income $20M, non-GAAP $45M

MANNKIND CORP

2024-Q3 EPS reported $0.07 revenue$208,728,000

Q3 total revenue $70.1M (+37% YoY); YTD revenue $208.7M (+49% YoY); YTD net income $20M.
Tyvaso DPI royalties up 34% to $27.1M (Q3) and 48% YTD to $75.3M; collaboration revenue +78% on manufacturing.
Afrezza net revenue up 12% to $15.0M (Q3); V-Go net revenue up 5% to $4.7M.
Pipeline: MNKD-101 Phase 3 global expansion; MNKD-201 Phase 1 complete, FDA meeting 1H 2025; INHALE-3 positive; pediatric data due Q4.
Cash and investments $268.4M; $5.3M bargain purchase gain from Pulmatrix deal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.